JCO Global Oncology最新文献

{"title":"Role of Social Media for Medical Oncologists and Medical Oncology Fellows (SMARTY): An Italian Cross-Sectional Study.","authors":"Elena Battaiotto, Carmine Valenza, Mattia Garutti, Luigi Orlando Molendini, Elena Bellio, Dario Trapani, Fabio Puglisi, Gabriella Pravettoni, Luca Buccoliero, Giuseppe Curigliano, Manuelita Mazza","doi":"10.1200/GO-24-00445","DOIUrl":"https://doi.org/10.1200/GO-24-00445","url":null,"abstract":"<p><strong>Purpose: </strong>The use of social media is transforming physician-patient communication, mainly in the field of medical oncology. The pattern of social media use by medical oncologists is poorly studied. Therefore, we developed a survey to understand the preferences, experiences, opinions, and expectations of Italian medical oncologists and oncology fellows regarding the use of social media in cancer medicine to identify the different profiles of social media users.</p><p><strong>Materials and methods: </strong>This multicentric, cross-sectional, observational study included oncologists or oncology fellows from Italy, who were surveyed from July to December 2023 on their use of social media. Data were analyzed through K-means clustering, and the Hartigan-Wong algorithm was applied to identify different profiles of social media users among the participants.</p><p><strong>Results: </strong>Of the 245 participants who accepted the invitation, 116 completed the entire survey and were included in the cluster analysis. Three profiles of social media users were identified through clustering: the highly social, the social skeptic, and the moderately social, accounting for 31%, 31%, and 38% of the participants, respectively. In general, older age (<i>P</i> = .0001), being a specialized oncologist (<i>P</i> = .003), and a higher mean time spent on social media (<i>P</i> = .0001) were associated with a greater consideration of the professional use of social media.</p><p><strong>Conclusion: </strong>The use of social media among medical oncologists and oncology fellows represents a spectrum ranging from the social skeptic user to the highly social. Age, professional status (specialist or fellow), and frequency on social media use were associated with different patterns, opinions, and behaviors related to social media use.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400445"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Cancers in Kerala, India: A Review of Population-Based Registry Data.","authors":"Jeffrey Mathew Boby, Deepak Varughese, Jame Mathew Benny, Mathew Thomas, Aju Mathew","doi":"10.1200/GO-24-00395","DOIUrl":"10.1200/GO-24-00395","url":null,"abstract":"<p><strong>Purpose: </strong>Kerala in India leads the nation in both Human Development Index and Sustainable Development Index. The state is a harbinger for the rest of the country in matters of health. Documentation of cancer trends and quantifying the cancer burden is crucial for planning oncology services in the country. In this study, we aim to perform a time series analysis using data from the National Cancer Registry.</p><p><strong>Methods: </strong>Data for crude incidence, age-adjusted incidence, and disease-specific incidence were extracted from published reports of the Population-Based Cancer registries at Kollam and Thiruvananthapuram. Data collected between 2006 and 2008 were analyzed and published in 2010. Data collected between 2012 and 2016 were published in 2020. Descriptive statistics was used for analysis.</p><p><strong>Results: </strong>Age-adjusted incidence rates increased from 121.7 per 100,000 men to 137.8 in Thiruvananthapuram from 2006-2008 to 2012-2016 period. Among women, in Thiruvananthapuram, the age-adjusted rates increased from 108.3 to 127.3. In Kollam, the age-adjusted incidence rate increased from 113.3 to 127.1 among men and 89.7 to 107.1 among women. Lung and breast cancers remain the most common cancers among men and women.</p><p><strong>Conclusion: </strong>There has been an increase in both crude and age-adjusted incidence rates in Kerala. However, these changes are in line with global trends in cancer incidence. Lifestyle changes and reduced tobacco and alcohol use will help decrease the incidence of cancer in Kerala.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400395"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observational Study of Best Supportive Care With or Without Oral Capecitabine in Patients With Metastatic Gallbladder Carcinoma at a Tertiary Center in India.","authors":"Abhinav Srivastava, Shagun Misra, Neeraj Rastogi, Vishwas Kapoor, Shaleen Kumar","doi":"10.1200/GO-24-00341","DOIUrl":"10.1200/GO-24-00341","url":null,"abstract":"<p><strong>Purpose: </strong>To compare overall survival (OS), toxicity, and quality of life (QOL) in patients with metastatic gallbladder cancer receiving oral capecitabine (X) with best supportive care (BSC) and BSC alone.</p><p><strong>Materials and methods: </strong>Patients with metastatic gallbladder cancer and Karnofsky Performance Status (KPS) ≥70 were accrued and assigned to either arm A or B. Assignment to these two arms was based on physician/patient discretion. Arm A received oral capecitabine 825 mg/m² twice a day d1-14, repeated every 3 weeks for six cycles with BSC, and arm B received BSC alone. The Kaplan-Meier method computed OS and comparison was using a log-rank test. QOL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 administered at baseline, 3 months, and 6 months. The linear mixed-effects model was used for the longitudinal analysis of QOL.</p><p><strong>Results: </strong>Between December 2020 and April 2022, 64 patients diagnosed with metastatic gallbladder carcinoma and KPS ≥70 were accrued in the study, and 32 patients were assigned to each arm. In arm A versus B, the median age was 52 versus 55 (<i>P</i> = .21); the median KPS was 80 versus 70 (<i>P</i> = .008). The median OS in arm A versus B was 3.4 versus 2 months (<i>P</i> = .001). Grade 1-2 vomiting and diarrhea were seen in 50% versus 78% (<i>P</i> = .041) and 59% versus 9.3% (<i>P</i> = .01) patients in arm A versus B, respectively. Grade 1-2 hand-foot syndrome was seen in 12 (37.5%) patients in arm A. Dynamic changes showed an improvement in pain in the linear mixed model with a significant difference between the arms (<i>P</i> = .011); arm A experienced a significant improvement in pain over time (arm × time <i>P</i> = .020). Global QOL improved over time (<i>P</i> = .038) with parallel improvement between arms (arm × time <i>P</i> = .490).</p><p><strong>Conclusion: </strong>Compared with BSC alone, patients who receive X + BSC experience an OS improvement of 1.4 months and better pain control without grade 3 toxicities or negative impact on QOL.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400341"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study.","authors":"Abigia Ashenafi, Soliyana Demelash, Efrata Melaku, Haymanot Abe, Meron Yitna, Fisseha Tekle, Jiksa Dabessa, Biniam Araya, Yared Nigussie, Wondmagegn Demsiss, Ashenafi Zelalem, Song Jung Kim, Nebiyu Dereje","doi":"10.1200/GO-24-00468","DOIUrl":"https://doi.org/10.1200/GO-24-00468","url":null,"abstract":"<p><strong>Purpose: </strong>To analyze survival and its predictors among patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in Ethiopia.</p><p><strong>Materials and methods: </strong>We conducted a retrospective cohort study among patients who received TACE for HCC at MCM Hospital from December 1, 2016, to December 31, 2022. Data were extracted from patients' medical records, and vital status was ascertained from the patients' charts or by phone call to the next of kin. We used Kaplan-Meier estimator to determine survival functions and log-rank test to compare the survival functions in different groups. Predictors of survival were identified using a multivariable Cox proportional hazards regression model as expressed by adjusted hazard ratio (aHR).</p><p><strong>Results: </strong>Of the total 257 patients included in the study, 68.9% were male, with a mean age of 56.5 (±14.06) years, and 86% were diagnosed at the advanced stage of the cancer (Barcelona Clinic Liver Cancer-C). The median overall survival was 12.7 months (95% CI, 10.57 to 14.85), and the overall survival rate at 1 year, 2 years, 3 years, 4 years, 5 years, and 6 years was found to be 58.0% (95% CI, 51.8% to 63.8%), 24.1% (95% CI, 19.1% to 29.6%), 8.2% (95% CI, 5.1% to 11.7%), 7.0% (95% CI, 3.9% to 10.1%), 1.6% (95% CI, 0.4% to 3.1%), and 1.2% (95% CI, 0.1% to 2.7%), respectively. The probability of death was significantly increased by alpha-fetoprotein level <400 ng/mL (aHR, 5.72 [95% CI, 1.52 to 21.51]), albumin level (aHR, 5.03 [95% CI, 1.41 to 18.01]), and bilobar distribution (aHR, 5.67 [95% CI, 1.40 to 23.04]).</p><p><strong>Conclusion: </strong>The findings of the study underscore the need for the expansion of preventive measures and treatment facilities to address the overwhelming burden of HCC in Ethiopia.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400468"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forecasting Asparaginase Need and Cost for Childhood Cancer Using ACCESS FORxECAST.","authors":"Terence M Hughes, Nitin Shrivastava, Lewis B Silverman, A Lindsay Frazier, Sumit Gupta, Avram Denburg","doi":"10.1200/GO-24-00444","DOIUrl":"https://doi.org/10.1200/GO-24-00444","url":null,"abstract":"<p><strong>Purpose: </strong>Asparaginase (ASN) is a critical component of pediatric ALL protocols. Until recently, ASN was available in three formulations: native Escherichia coli, PEGylated E. coli (PEG), and Erwinase, with native E. coli typically more accessible in low- and middle-income countries (LMICs). Short shelf lives, intermittent availability, and concern for substandard formulations in LMICs have created a need for proactive ASN demand estimates.</p><p><strong>Methods: </strong>We adapted FORxECAST, a pediatric cancer drug forecasting model, to focus on ASN for pediatric ALL. The model is adaptable to user data and defaults to best available public data where local data are unavailable. We forecast ASN quantity and cost in three case study countries for four scenarios using two regimens-base regimen (BR) and intensified regimen (IR)-outlining how quantity and costs vary on the basis of ASN formulation, dose, and second-line availability.</p><p><strong>Results: </strong>Native E. coli is cheaper than PEG for first-line treatment across all scenarios. Regimen intensification from BR to IR requires a substantially higher cost when PEG is used relative to native E. coli. The cost of treating ASN hypersensitivity with Erwinase for BR in Burundi, Ghana, and Turkmenistan is $19,660 in US dollars (USD), $24,800 USD, and $15,246 USD, respectively.</p><p><strong>Conclusion: </strong>Treatment intensification requires a cost increase that should be accessible for most LMICs, but PEG utilization is substantially more costly, suggesting that prioritizing investment in intensifying treatment using native E. coli is the least costly approach to maximize treatment availability. Cost savings associated with native E. coli utilization may liberate funds for Erwinase procurement for patients with ASN hypersensitivity. Future analyses needed include an evaluation of costs associated with preventing abandonment due to compliance complexity with native E. coli given increased administration frequency compared with PEG.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400444"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Observational Study on Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer in Rwanda: Acute Toxicity in Patients.","authors":"Felix Sinzabakira, W D Heemsbergen, Pacifique Mugenzi, A Diane Ndoli, Theoneste Maniragaba, Claire Umubyeyi, Fidel Rubagumya, Emmanuel Mutabazi, Luca Incrocci","doi":"10.1200/GO-24-00311","DOIUrl":"https://doi.org/10.1200/GO-24-00311","url":null,"abstract":"<p><strong>Purpose: </strong>Moderate hypofractionation (MHF) offers logistical and financial advantages, and has become standard in Western countries but not yet in Africa. This study assessed GI and genitourinary (GU) acute toxicity in Rwandan men undergoing MHF (20 × 3 Gy) treatment.</p><p><strong>Materials and methods: </strong>Since 2021, patients with prostate cancer at the Rwanda Cancer Centre have been informed about the study on MHF treatment and could participate by signing an informed consent. The study included patients with confirmed prostate adenocarcinoma (any T, any prostate-specific antigen any Gleason score, N0M0), excluding those with inflammatory bowel disease, previous pelvic irradiation, or previous prostatectomy. Participants received 20 fractions of 3 Gy over 4 weeks using the volumetric modulated arc radiotherapy (RT) technique with a 6 megavoltage linear accelerator. GI and GU acute toxicity was evaluated at week 2, at the end of RT, and 3 months after treatment using the Radiation Therapy Oncology Group (RTOG) acute toxicity grading system.</p><p><strong>Results: </strong>Fifty consecutive patients with localized prostate cancer were included. The median patient age was 70 years. Most patients (86%) had high-risk disease and 94% received androgen-deprivation therapy. The cost and treatment time were reduced by 50%. The distribution of maximum acute RTOG toxicity scores were for GI 10% grade 0, 70% grade 1, 20% grade 2, 0% grade 3, and for GU scores were 0%, 40%, 54%, and 6%, respectively. By 3 months, RT symptoms had returned to baseline levels for most patients.</p><p><strong>Conclusion: </strong>MHF (20 × 3 Gy) was well tolerated in men treated for prostate cancer in Rwanda, showing that MHF is feasible in an African setting. However, further research on acute and late toxicity for more patients is warranted.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400311"},"PeriodicalIF":3.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142869376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Medical Tourism for Cancer Treatment: Trends, Trajectories, and Perspectives From African Countries.","authors":"","doi":"10.1200/GO-24-00565","DOIUrl":"https://doi.org/10.1200/GO-24-00565","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400565"},"PeriodicalIF":3.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases.","authors":"Swapnil Patel, Ramakrishnan Ayloor Sheshadri, Avanish Saklani, Somashekhar Sp, Rohit Kumar, Shivendra Singh, Vivek Sukumar, Aditi Bhatt","doi":"10.1200/GO-24-00306","DOIUrl":"https://doi.org/10.1200/GO-24-00306","url":null,"abstract":"<p><strong>Purpose: </strong>This manuscript reports the results of the Indian Network for Development of Peritoneal Surface Oncology and Indian Society of Peritoneal Surface Malignancies (INDEPSO-ISPSM) consensus that aimed to provide recommendations for some important aspects management of patients with colorectal peritoneal metastases (CPM) and address some issues unique to India.</p><p><strong>Methods: </strong>The modified Delphi technique was used with two rounds of voting. There were 29 questions on nine main topics-the role of cytoreductive surgery (CRS), patient selection for CRS, preoperative workup, role of systemic chemotherapy (SC), CPM with other visceral metastases, molecular profile, hyperthermic intraperitoneal chemotherapy (HIPEC) and other modalities of intraperitoneal chemotherapy (IPC), prophylactic/preventive strategies, and surveillances after CRS. A consensus was achieved if anyone option received >70 votes (strong consensus >90%).</p><p><strong>Results: </strong>Forty-eight surgical (n = 41) and gastrointestinal (n = 7) oncologists were invited; 44 agreed to participate. The response rate was 95.4% (42/44) in round 1 and 93.1% (41/44) in round 2. Overall, a consensus was achieved on 23/29 (79.3%) questions (strong consensus on 6/29 [20.6%]). The panel strongly recommended considering surgery for limited CPM with limited liver metastases (92.5%), not altering the surgical approach in patients with <i>KRAS</i> mutations (91.67%), and limiting the use of IPC for unresectable CPM outside clinical trials (95%). Adjuvant SC was recommended for all patients undergoing CRS (89.47%). CRS is a therapeutic option for selected patients with CPM including those with metachronous CPM (79.49) and signet ring cell cancers (76.92%). HIPEC was recommended outside clinical trials only for patients with peritoneal cancer index 11-15(80%).</p><p><strong>Conclusion: </strong>The panel recommended CRS for most indications but was very selective in recommending HIPEC and IPC outside clinical trials. These recommendations should be a useful resource in clinical decision making for clinicians treating CPM in India and regions with a similar sociodemographic background.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400306"},"PeriodicalIF":3.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevating Cancer Care Standards Worldwide: An Analysis of Global Initiatives and Progress.","authors":"Andres Wiernik, Alvaro Rogado, Deirdre O'Mahony, Albiruni R Abdul Razak","doi":"10.1200/GO.24.00199","DOIUrl":"https://doi.org/10.1200/GO.24.00199","url":null,"abstract":"<p><p>Cancer remains a widespread and significant global health issue, with consequential impacts on individuals, families, and societies across the globe. Although there have been noteworthy advancements in the prevention, diagnosis, treatment, and study of cancer, the impact of this disease continues to be significant on health care systems and people worldwide. Furthermore, there are still differences in obtaining the advantages of modern cancer treatment, which can partly be attributed to the lack of standardized standards for providing top-notch cancer care. To tackle these difficulties, a multitude of projects and organizations have emerged to address the standard of cancer care on a global level. This paper provides a comprehensive review and analysis of the worldwide influence of programs and organizations that seek to improve the quality of cancer care. This document examines the progression of these initiatives, their cooperation with international organizations, possible paths for additional advancement, and suggestions for enhancing the standard of cancer treatment worldwide.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400199"},"PeriodicalIF":3.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142869374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country.","authors":"Juan-Manuel Hernandez-Martinez, Alberto Guijosa, Diana Flores-Estrada, Graciela Cruz-Rico, Jenny Turcott, Norma Hernández-Pedro, Enrique Caballé-Perez, Andrés F Cardona, Oscar Arrieta","doi":"10.1200/GO-24-00338","DOIUrl":"https://doi.org/10.1200/GO-24-00338","url":null,"abstract":"<p><strong>Purpose: </strong>Targeted therapies are indicated for patients with non-small cell lung cancer (NSCLC) and driver tumor mutations. However, real-world studies on the survival benefits of these agents are limited. This study aimed to evaluate the effect of targeted therapies matched to a genomic alteration on the survival of patients with NSCLC.</p><p><strong>Methods: </strong>This retrospective study included 446 patients with advanced NSCLC who underwent next-generation sequencing between 2016 and 2023 at the Instituto Nacional de Cancerología in Mexico. The primary outcomes were progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>For the entire cohort, the PFS and OS were 10.71 months (95% CI, 9.35 to 12.06) and 47.77 months (95% CI, 29.67 to 65.86). PFS was significantly longer in patients with actionable mutations treated with targeted therapies (19.41 months [95% CI, 14.27 to 24.55]; <i>P</i> < .001) than in patients without actionable mutations (6.4 months [95% CI, 4.4 to 8.4]) or not treated with targeted therapies (6.6 months [95% CI, 5.3 to 7.89]). Similarly, OS was significantly longer in patients with actionable mutations treated with targeted therapies (89.69 months [95% CI, 45.54 to 133.84]; <i>P</i> < .001) than in patients without actionable mutations (17.11 months [95% CI, 8.65 to 25.57]) or not treated with targeted therapies (22.3 months [95% CI, 12.48 to 32.1]). Survival gains were driven by significant improvements in PFS and OS in patients with <i>EGFR</i> and <i>ALK</i> mutations.</p><p><strong>Conclusion: </strong>This real-world data analysis demonstrated that targeted therapies improve the survival of patients with NSCLC with actionable mutations, which supports a recommendation for widening access to broad-based genomic testing and targeted therapies.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400338"},"PeriodicalIF":3.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}